Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)Depreciation ExpenseEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Vivos Therapeutics (VVOS) Depreciation Expense (2020 - 2025)

Historic Depreciation Expense for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to $400000.0.

  • Vivos Therapeutics' Depreciation Expense rose 30000.0% to $400000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 12000.0%. This contributed to the annual value of $600000.0 for FY2024, which is 0.0% changed from last year.
  • According to the latest figures from Q3 2025, Vivos Therapeutics' Depreciation Expense is $400000.0, which was up 30000.0% from $300000.0 recorded in Q2 2025.
  • Over the past 5 years, Vivos Therapeutics' Depreciation Expense peaked at $400000.0 during Q3 2025, and registered a low of $80597.0 during Q2 2021.
  • Moreover, its 5-year median value for Depreciation Expense was $200000.0 (2022), whereas its average is $172663.0.
  • As far as peak fluctuations go, Vivos Therapeutics' Depreciation Expense soared by 80067.26% in 2021, and later plummeted by 5000.0% in 2023.
  • Vivos Therapeutics' Depreciation Expense (Quarter) stood at $100000.0 in 2021, then surged by 200.0% to $300000.0 in 2022, then crashed by 33.33% to $200000.0 in 2023, then changed by 0.0% to $200000.0 in 2024, then surged by 100.0% to $400000.0 in 2025.
  • Its last three reported values are $400000.0 in Q3 2025, $300000.0 for Q2 2025, and $200000.0 during Q1 2025.